Profile data is unavailable for this security.
About the company
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
- Revenue in INR (TTM)15.81bn
- Net income in INR3.17bn
- Incorporated1984
- Employees1.57k
- LocationNeuland Laboratories Ltd'A' Block, Ground Floor, 8-2-120/113Rd No 2, Banjara Hills, Sanali Info ParkHYDERABAD 500033IndiaIND
- Phone+91 4 067611600
- Fax+91 4 067611600
- Websitehttps://www.neulandlabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shilpa Medicare Ltd | 11.23bn | -6.71m | 52.32bn | 1.03k | -- | -- | 49.20 | 4.66 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
Orchid Pharma Ltd | 8.12bn | 1.25bn | 53.56bn | 838.00 | 37.06 | -- | 33.70 | 6.60 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 65.35bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
F D C Ltd | 19.16bn | 2.90bn | 72.26bn | 6.37k | 25.18 | -- | 21.99 | 3.77 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
Marksans Pharma Ltd | 21.03bn | 3.17bn | 76.95bn | 1.40k | 24.09 | -- | 19.88 | 3.66 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
Procter & Gamble Health Ltd | 12.37bn | 2.27bn | 78.46bn | 1.41k | 34.61 | 9.74 | 31.08 | 6.34 | 136.55 | 136.55 | 745.23 | 485.49 | 1.15 | 2.51 | 10.40 | 8,791,756.00 | 21.02 | -- | 27.67 | -- | 69.97 | -- | 18.32 | -- | 2.79 | 383.03 | 0.0132 | -- | 10.34 | -- | 19.19 | -- | -- | -- |
Strides Pharma Science Ltd | 39.53bn | -1.52bn | 82.10bn | 2.85k | -- | -- | 138.79 | 2.08 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
Wockhardt Ltd | 27.76bn | -5.01bn | 87.26bn | 2.74k | -- | -- | -- | 3.14 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 96.70bn | 1.57k | 30.50 | -- | 25.87 | 6.12 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 97.41bn | 407.00 | -- | -- | -- | 91.31 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
Granules India Ltd | 45.26bn | 3.95bn | 100.46bn | 3.65k | 25.40 | -- | 16.80 | 2.22 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
Glenmark Life Sciences Ltd | 23.68bn | 5.19bn | 101.24bn | 1.82k | 19.50 | -- | 17.77 | 4.28 | 42.36 | 42.36 | 193.15 | -- | -- | -- | -- | 12,982,110.00 | -- | -- | -- | -- | 55.92 | -- | 21.93 | -- | -- | 538.47 | -- | -- | 1.79 | -- | 11.52 | -- | -- | -- |
Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 101.36bn | 777.00 | 23.28 | -- | 20.70 | 6.22 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
Jubilant Pharmova Ltd | 66.22bn | 378.60m | 108.52bn | 1.03k | 282.81 | -- | 18.51 | 1.64 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Eris Lifesciences Ltd | 18.61bn | 3.86bn | 120.13bn | 3.55k | 31.13 | -- | 22.13 | 6.46 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 131.14bn | 947.00 | 94.15 | -- | 84.75 | 10.96 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
Holder | Shares | % Held |
---|---|---|
Matthews International Capital Management LLCas of 30 Sep 2023 | 522.35k | 4.07% |
HSBC Asset Management (India) Pvt Ltd.as of 31 Mar 2024 | 333.00k | 2.60% |
quant Money Managers Ltd.as of 30 Sep 2023 | 192.07k | 1.50% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 172.33k | 1.34% |
Ocean Dial Asset Management Ltd.as of 30 Sep 2023 | 170.89k | 1.33% |
Ocean Dial Advisers Pvt Ltd.as of 31 Jan 2024 | 113.99k | 0.89% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 92.73k | 0.72% |
BlackRock Fund Advisorsas of 04 Apr 2024 | 80.30k | 0.63% |
WhiteOak Capital Asset Management Ltd.as of 31 Mar 2024 | 65.65k | 0.51% |
Bandhan Asset Management Co. Ltd.as of 31 Mar 2024 | 51.43k | 0.40% |